Entrada Therapeutics, Inc. TRDA
At closeNov 3, 2026, 4:01 PM EST
After hours · Nov 3, 4:01 PM ET
- YTD
- -54.09%
- 1 year
- -30.38%
- Market cap
- 183.78M
- Revenue (ttm)
- 215.23M
- Profit margin
- 25.53%
- EPS (ttm)
- -3.96
- Shares out
- 37.42M
- Forward P/E
- -5.54
- YTD return
- -54.09%
- 1-year return
- -30.38%
- Volume
- 563.12K
- Avg volume
- 346.66K
- Open
- 5.08
- Previous close
- 5.11
- Day's range
- 4.62 – 5.08
- 52-week range
- 4.11 – 16.45
- Beta
- -0.27
- Price target
- 26.43 (+459.9%)
- Earnings date
- Aug 13, 2024
2Y -13.07 (-73.55%)
Key statistics
- Enterprise value
- 234.75M
- PEG ratio
- 0.00
- Price / sales
- 3.04
- Price / book
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -55.30%
- Free cash flow
- -29.26M
- Total cash
- 449.34M
- Total debt
- 61.31M
- Return on equity
- 16.42%
- Short % of float
- 6.53%
- 50-day average
- 18.48
- 200-day average
- 15.77
Analyst view
- Target (low)
- 20.00
- Target (mean)
- 26.43
- Target (high)
- 29.00
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.664.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -0.67 | -0.35 | +0.32 | +47.76% |
| Aug 13, 2024 | Jun 1, 2024 | 0.65 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.65 | 1.55 | +0.90 | +138.46% |
| May 7, 2024 | Mar 1, 2024 | -0.38 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.38 | 0.68 | +1.06 | +278.95% |
| Mar 13, 2024 | Dec 1, 2023 | -0.07 | -0.29 | -0.22 | -314.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Roth MKM | init | — | Buy |
| Nov 6, 2024 | Oppenheimer | main | Outperform | Outperform |
| Nov 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 26, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Aug 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 25, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- entradatx.com
News
Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR) 
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer 
What's Going On With Entrada Therapeutics Stock Wednesday? 
Entrada Therapeutics Announces Independent Data Monitoring Committee Review Of All Available Safety And PK Data From The Eight Participants Enrolled In Cohort 2 Of The Double-Blind, Placebo-Controlled, Multiple Ascending Dose Portion of ELEVATE-44-201 
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study 
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity 
Alpha Buying: Follow the Money From NVIDIA and Merck 
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program 
BlackRock Inc. Invests $19.01 Million in Entrada Therapeutics, Inc. $TRDA
Your note
Sign in to keep a note on TRDA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DOSHI DIPAL | Chief Executive Officer | Sale | Jul 14, 2024 | 334,475 |
| DOWDEN NATHAN J | President | Sale | Sep 25, 2024 | 125,149 |
| KIM PETER S | Director | Conversion of Exercise of derivative security | Jun 2, 2024 | 104,330 |
| KREHER NERISSA C | Officer | Sale | Sep 5, 2023 | 40,037 |
| SETHURAMAN NATARAJAN | Officer | Sale | Dec 2, 2024 | 144,997 |
| WENTWORTH KORY JAMES | Chief Financial Officer | Conversion of Exercise of derivative security | Dec 1, 2024 | 73,849 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 13.00% | 4,865,819 | 84.96M | Sep 29, 2024 |
| MPM Asset Management, LLC | 11.83% | 4,425,784 | 77.27M | Sep 29, 2024 |
| 5AM Venture Management, LLC | 11.78% | 4,408,379 | 76.97M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 8.15% | 3,049,572 | 53.25M | Sep 29, 2024 |
| Blackrock Inc. | 4.87% | 1,822,835 | 31.83M | Sep 29, 2024 |
| FMR, LLC | 4.66% | 1,743,498 | 30.44M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 5.19% | 1,942,377 | 33.91M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 1.81% | 677,414 | 11.83M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.70% | 634,828 | 11.08M | Oct 30, 2024 |
| Price (T.Rowe) New Horizons Trust | 1.20% | 449,109 | 7.84M | Sep 29, 2024 |
| Fidelity Growth Company Fund | 0.96% | 357,801 | 6.25M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 0.83% | 309,169 | 5.40M | Oct 30, 2024 |